Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insights: Addressing the Physical and Emotional Challenges of Children and Adolescents With Psoriasis
  • CME
  • CE

Credits Available
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Nurse Practitioners: 0.75 NAPNAP CE contact hour, 0.25 pharmacology content
Released: February 7, 2022 Expiration: February 6, 2023
Start Activity
Provided by Clinical Care Options, in collaboration with the National Association of Pediatric Nurse Practitioners.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 

Contact NAPNAP

For customer support please email: ce@napnap.org

Mailing Address
5 Hanover Square
Suite 1401
New York, NY 10004

Supported by an educational grant from
Novartis Pharmaceuticals Corporation
Victoria Garcia-Albea, NP, DCNP
Robert Sidbury, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize differences in the clinical presentation of psoriasis in infants, children, and adolescents
  • Explore strategies to address psychosocial and quality of life concerns in pediatric patients with psoriasis
  • Identify the appropriate use of novel and emerging therapies for psoriasis in pediatric patients
  • Apply appropriate strategies for screening for juvenile psoriatic arthritis and other comorbidities in pediatric patients with psoriasis

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Victoria Garcia-Albea, NP, DCNP

Director, Lahey Dermatology
Nurse Practitioner
Training Program
Lahey Hospital and Medical Center
Burlington, Massachusetts

Victoria Garcia-Albea, NP, DCNP, has disclosed that she has received consulting fees from Sanofi Genzyme.
Robert Sidbury, MD, MPH

Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

Robert Sidbury MD, MPH, has disclosed that he has received funds for research support from Galderma, Micreos, Regeneron, and UCB.

Staff

Craig Borders
Vice President, Managing Scientific Director
Craig Borders has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for dermatology, rheumatology and pediatric physicians, nurse practitioners, nurses and other healthcare professionals who manage patients with psoriatic disease.

Goal

The goal of this activity is to improve disease outcomes, quality of life, and psychosocial development in children and adolescents with psoriasis by improving the knowledge and competence of healthcare professionals providing psoriasis care for pediatric patients.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

This program is accredited for 0.75 NAPNAP CE contact hour of which 0.25 contain pharmacology content, per the National Association of Pediatric Nurse Practitioners Continuing Education Guidelines.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 07, 2022, through February 06, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Comorbidities
  • CME
  • CE

Loading...
In this engaging, interactive video roundtable, expert faculty review the clinical presentation of psoriasis in infants, children, and adolescents, and discuss strategies to address psychosocial elements of the disease in these patients. Additional discussion covers novel and emerging therapies as well as screening for common comorbidities, including juvenile psoriatic arthritis.
Victoria Garcia-Albea, NP, DCNP
Robert Sidbury, MD, MPH
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Nurse Practitioners: 0.75 NAPNAP CE contact hour, 0.25 pharmacology content
Released: February 7, 2022 Expiration: February 6, 2023

This program is divided into several short segments that you can step through using the Video Chapters menu.

Related Content

Commentary on new and emerging therapies, reducing healthcare disparities, and engaging patients in decision-making to optimize psoriasis care, from Clinical Care Options (CCO).

Steven Feldman, MD, PhD Released: September 16, 2022

Expert slides on new and emerging therapies, reducing healthcare disparities, and improving medication adherence in the management of moderate to severe psoriasis

Steven Feldman, MD, PhD Melodie S. Young, MSN, A/GNP-c Released: September 9, 2022

Slideset with expert insights into current and future management of pustular psoriasis from PCE and CCO.

person default Alice Gottlieb, MD, PhD person default Kristine Kucera, PA-C, MPAS, DHSc Released: September 9, 2022

Slides featuring expert discussion of managing the physical and emotional elements of pediatric psoriasis

Victoria Garcia-Albea, NP, DCNP Robert Sidbury, MD, MPH Released: February 8, 2022

Video Chapters


Provided by Clinical Care Options, in collaboration with the National Association of Pediatric Nurse Practitioners.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 

Contact NAPNAP

For customer support please email: ce@napnap.org

Mailing Address
5 Hanover Square
Suite 1401
New York, NY 10004

Supported by an educational grant from
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings